Subscribe To
Ericsson (eric) showcases industry first virtualized cloud ran
Ericsson (ERIC) demonstrates the industry's first virtualized cloud RAN solution, leveraging 4th Gen Intel Xeon Scalable processors with Intel vRAN Bo...
June 14, 2023, 12:28 pm
Ready capital announces pricing of rcmf 2023-fl12, a securitization of $648.6 million in bridge loans and the redemption of rcmf 2020-fl4
Transaction Represents the Company’s 12th CRE CLO NEW YORK, June 12, 2023 (GLOBE NEWSWIRE) — Ready Capital Corporation (NYSE: RC) (“Ready Capita...
June 12, 2023, 8:15 pm
Exelixis: thriving investment opportunity in the evolving world of oncology
Revenue-generating products like Cabometyx and strategic partnerships with industry leaders, such as Genentech, contribute to Exelixis' impressive fin...
May 28, 2023, 5:49 am
Boj to maintain yield curve control policy until at least next year - poll
6/24 (25%) economists expect BOJ to end yield curve control (YCC) this year11/24 economists expect BOJ to end YCC in 20245/24 economists expect BOJ to...
May 26, 2023, 4:18 am
Leap therapeutics to present updated data from part a of the distinguish study of dkn-01 plus tislelizumab and chemotherapy in gastric cancer patients at the 2023 asco annual meeting
19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient wit...
May 25, 2023, 5:10 pm
Ayala pharmaceuticals announces first quarter 2023 financial results and provides corporate update
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 23, 2023 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology co...
May 23, 2023, 5:20 pm
Andrada appoints barclays to advise on uis plans after numerous partnership proposals
Andrada Mining Ltd (AIM:ATM, OTC:AFTTF) said it has appointed Barclays' investment banking arm as a strategic adviser after receiving "numerous" unso...
May 11, 2023, 3:10 am
Arbutus biopharma clinical hold slows hepatitis b momentum: broker
Analysts at Baird Equity Research have awarded Arbutus Biopharma a ‘Neutral' rating after the early-stage biopharmaceutical company announced that ...
April 26, 2023, 2:44 pm
Arbutus announces fda clinical hold on ind application for ab-101, an oral pd-l1 inhibitor
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-sta...
April 25, 2023, 11:30 am
Factbox: reactions to ruling on french pension reform
PARIS (Reuters) – France’s Constitutional Court on Friday cleared plans by the government of President Emmanuel Macron to raise the legal retireme...
April 14, 2023, 4:46 pm
Theratechnologies to present preclinical data at aacr demonstrating synergy between th1902 and anti-pd-l1 immunotherapy in cold tumor model
MONTREAL, March 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biophar...
March 14, 2023, 6:42 pm
Pd-1/pd-l1 inhibitors market to record a cagr of 9.6% & to reach a valuation of usd 123.3 billion by 2033 – exclusive report by future market insights, inc.
Increasing Government Cancer-fighting Measures, Growing Healthcare Expenses, and Increased Public Awareness are anticipated to Propel the Industry Ahe...
March 3, 2023, 11:30 am
Onl therapeutics receives u.s. fda clearance of investigational new drug application for onl1204 ophthalmic solution
First-in-class small molecule Fas inhibitor with unique mechanism of action is designed to provide neuroprotection for retinal cells ANN ARBOR, Mich.,...
February 1, 2023, 12:00 pm
Astrazeneca posts mixed results from lung cancer trial
AstraZeneca shares slipped as it reported mixed results from its latest trial (PEARL) of the cancer drug Imfinzi. Using Imfinzi as a single therapy fo...
December 19, 2022, 4:16 am
Prometheus biosciences soars as new data indicates therapeutic candidate holds promise for bowel disease
Prometheus Biosciences Inc shares have rocketed more than 170% on positive results for its therapeutic candidate PRA023 in both its ARTEMIS-UC Phase 2...
December 7, 2022, 12:07 pm
Rapt therapeutics to present flx475 phase 1/2 data at the european society for medical oncology (esmo) immuno-oncology annual congress
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-s...
November 30, 2022, 7:05 pm
Revisiting tracon pharmaceuticals
Today, we look back in on clinical stage developmental firm TRACON Pharmaceuticals for the first time since early 2021. The company's primary drug can...
November 30, 2022, 1:43 am
Alector presents results from first-in-human phase 1 study of al101 for the treatment of neurodegenerative diseases
Al101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for ...
November 29, 2022, 4:05 pm
Rocket pharmaceuticals: 2 regulatory filings in 2023 could propel it higher
A Rocket Pharmaceuticals, Inc. regulatory filing to the FDA of LV RP-L201 for Leukocyte Adhesion Deficiency-I is expected in the 1st half of 2023. A r...
November 29, 2022, 10:50 am
Tracon pharmaceuticals doses first patient in drug trial to treat malignant tumours
TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has dosed the first patient in a Phase 1/2 trial evaluating the company's CTLA-4 antibody, YH001, in...
November 21, 2022, 8:41 am
